MarkHerz Inc., a biotechnology company specializing in AAV-based gene therapies targeting cardiovascular and metabolic diseases, announced that it has signed a Memorandum of Understanding (MOU) on May ...

Paving the Way for European Clinical Entry and Global Technology Transfer A Milestone Partnership Highlighting Korea's Expanding Influence in Global Biotech Innovation MarkHerz Inc., a biotechnology ...